================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------
FORM 8-K
---------------------
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): November 27, 2001
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-28150 33-0525145
(State or other (Commission File Number) (IRS Employer
jurisdiction of Identification Number)
incorporation)
10555 SCIENCE CENTER DRIVE, SAN DIEGO, CA 92121
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (858) 658-7600
N/A
(Former name or former address, if changed since last report.)
================================================================================
This Current Report on Form 8-K is filed by Neurocrine Biosciences, Inc., a
Delaware corporation (the "Company"), in connection with the matters described
herein.
ITEM 5. OTHER EVENTS
On November 27, 2001, the Company announced the dosing of seven subjects in
the initiation of a Phase I clinical trial with the Company's proprietary,
orally active, gonadotropin-releasing hormone antagonist. A copy of the
Company's press release announcing the initiation of the clinical trial, dated
November 27, 2001, is attached hereto as Exhibit 99.1 and incorporated herein by
reference.
ITEM 7. EXHIBITS
(c) Exhibits. The following exhibits are filed herewith:
Exhibit
Number Description of Exhibit
------ ----------------------
99.1 Press Release, dated November 27, 2001.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Dated: November 27, 2001 /s/ Paul W. Hawran
----------------- ------------------
Paul W. Hawran
Executive Vice President
and Chief Financial Officer
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
-------- ------------------------------------------------------------
99.1 Press Release, dated November 27, 2001.